Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Chondrosarcoma Clinical Trial

Official title:

A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01330966
• Other study ID #: AAPSMCS1002
• Status: Completed
• Phase: Phase 2
• Start date: April 2011
• Est. completion date: February 2018

Study information

• Verified date: March 2023
• Source: George Clinical Pty Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma.

Description:

This research study is being conducted in adult subjects with a type of bone cancer called chondrosarcoma that has spread to other parts of the body and is not able to be removed with surgery. There is only one study drug that will be used in this study. It is a drug that interferes with cell communication and growth, taken orally. The study drug is called pazopanib.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. completion date: February 2018
• Est. primary completion date: February 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent.

• Age > or = to 18 years.

• Histologically confirmed diagnosis of conventional chondrosarcoma of any grade.

• Surgically unresectable or metastatic disease.

• Any number of prior treatment regimens, including treatment naive subjects. Prior treatment with tyrosine kinase inhibitors is permitted.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

• Measurable or evaluable (non-measurable) disease per RECIST guidelines version 1.1.

• Adequate organ system function determined within 14 days prior to first dose of study treatment.

• Left ventricular ejection fraction > 50% or the institutional LLN within 28 days prior to the first dose of study treatment.

• Females must either be of non-child bearing potential or have a negative serum pregnancy test within 7 days prior to the first dose of study treatment.

Exclusion Criteria:

• Prior treatment with pazopanib.

• Mesenchymal, dedifferentiated, and extraskeletal myxoid chondrosarcoma subtypes.

• Prior malignancy (Note: subjects who have had another malignancy and have been disease-free for 3 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible).

• History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, unless previously treated, asymptomatic, and off steroids and anti-seizure medication for 6 months prior to first dose of study drug.

• Clinically significant gastrointestinal (GI) abnormalities that may increase the risk for GI bleeding.

• Clinically significant GI abnormalities that may affect absorption of investigational product.

• Presence of uncontrolled infection.

• Corrected QT interval > 480 msecs using Bazett's formula.

• History of certain cardiovascular conditions within the past 6 months.

• Poorly controlled hypertension [defined as systolic blood pressure of > or = 140 mmHg or diastolic blood pressure of > or = 90 mmHg].

• History of cerebrovascular accident including transient ischemic attack, pulmonary embolism, or untreated deep venous thrombosis within the past 6 months.

• Prior major surgery or trauma within 28 days prior to the first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer.

• Evidence of active bleeding or bleeding diathesis.

• Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage.

• Hemoptysis in excess of 2.5 mL within 8 weeks of first dose of study drug.

• Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.

• Unable or unwilling to discontinue use of prohibited medications for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of study treatment.

• Radiation therapy, surgery (except major surgery), tumor embolization, chemotherapy, immunotherapy, biologic therapy, investigational therapy, or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug.

• Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia.

• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or excipients that contraindicates participation.

Related Conditions & MeSH terms

• Chondrosarcoma
• Metastatic Chondrosarcoma

Intervention

Drug:
• pazopanib
Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.

Locations

Country	Name	City	State
United Kingdom	University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre	Edgbaston	Birmingham
United States	City of Hope	Duarte	California
United States	MD Anderson	Houston	Texas
United States	University of Iowa	Iowa City	Iowa
United States	Edward Cancer Center	Naperville	Illinois
United States	Pennsylvania Oncology Hematology Associates	Philadelphia	Pennsylvania
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
George Clinical Pty Ltd	GlaxoSmithKline

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease Control at Week 16	Disease control at week 16 defined as complete response (CR), Disappearance of all target lesions; plus partial response (PR), At least a 30% decrease in the sum of diameters of the target lesions taking as reference the Baseline sum diameters; plus stable disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum diameters while on the study; where tumor response is defined by RECIST (Response Evaluation Criteria in Solid Tumors) guidelines version 1.1. Repeat radiologic imaging is performed after every 2 cycles of treatment (approximately every 8 weeks).	Assessed at week 16 of study treatment
Secondary	Progression Free Survival (PFS)	The time origin for PFS will be cycle 1 day 1. Repeat radiologic imaging will be conducted after every 2 cycles of treatment (approximately every 8 weeks). No upper limits of duration of assessment are identified or defined in the protocol.	Cycle 1 day 1 until the subject experiences disease progression
Secondary	Overall Survival (OS)	The time origin for OS will be cycle 1 day 1. Subjects will be followed until 6 months after end of treatment, lost to follow-up, or withdrawal of consent. No upper limits of duration of assessment are identified or defined in the protocol.	Cycle 1 day 1 until 6 months after end of treatment, is lost to follow-up, or withdraws consent